Royalty Report: Drugs, Disease, Biotechnology – Collection: 6547

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Disease
  • Biotechnology
  • Diagnostic
  • Therapeutic
  • Pharmaceuticals

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 6547

License Grant
The Australian Licensee entered into a patent assignment and License Agreement with a University in Australia.
License Property
The Agreement provided for the assignment of various patents and patent rights to the Licensee comprised of an international patent application entitled, ‘A method of assaying and treating Alzheimer Disease.’

The invention is directed to a method for assaying for Alzheimer’s disease and to a method for treating the disease by modulating divalent or trivalent cation and/or heparin interaction in a patient with Amyloid Precusor Protein, or APP. The technologies or products that may arise from the invention include therapeutic agents such as zinc binding agents that modulate processing of APP, as well as a screening assay for Alzheimer’s disease to determine the amount of various forms of APP in the circulatory system of a human compared to a control sample to determine presence of the disease.

IPSCIO Record ID: 7285

License Grant
The Licensee entered into a patent assignment and intellectual property licensing Agreement with the Licensor, under which two patent applications were assigned to the Licensee.

On September 10, 2007, we executed an Assignment and Novation Deed under which all  rights and obligations under the patent assignment agreement were assigned.

License Property
One is an international patent application (PCT application) entitled ‘Beta-Amyloid Peptide Inhibitors’ which is granted in Australia, Canada and in the United States and in prosecution in Europe and Japan.  The invention is directed to compounds which block the metal binding site on Beta-Amyloid.  The technologies or products that may arise from this invention include metallo-based compounds as therapeutics or preventative treatments for Alzheimer’s disease.  

The other patent entitled ‘Method of Screening for inhibitors of Alzheimer’s Disease,’ an Australian provisional application that matured into a patent application in the United States, was allowed to lapse in the second half of 2009.

IPSCIO Record ID: 5850

License Grant
The Licensor, a nonprofit American academic medical center, grants to Licensee a non-exclusive License in the territory within the Field of Use, without the right to subLicense (except to its Affiliates), to use and breed the Licensed Technology, and to use the Licensed Know-How, under the Mayo Patent Rights, according to the terms of this LSRA.
License Property
Licensed Technology means mice of the Tg 2576 strain of the transgenic mouse model described in Hsiao et al, Correlative Memory Deficils, A-Beta Elevation and Amyloid Plaques in Transgenic.  All reference to the singular shall include the plural and vice-versa.  169 Patent Rights mean U.S. Patent Number 5,455,169, issued October 3, 1995. MAYO believes that dissemination of these transgenic mice to researchers is of potential great benefit to present and future patients having Alzheimer's Disease and other neurodegenerative diseases.

DEVELOPMENT PROGRAMS. means pharmaceutical, biotechnological and diagnostic development programs in the field of Alzheimer's Disease and other central nervous system and neurodegenerative diseases as performed by LICENSEE or its Affiliates.

LICENSED TECHNOLOGY. means (a) mice of the Tg 2576 strain of the transgenic mouse model described in Hsiao et al, Correlative Memory Deficils, A-Beta Elevation and Amyloid Plaques in Transgenic Mice, as published in Science on October 4, 1996, or in a U.S. continuation-in-part patent application, filed June 17, 1996, Serial No. 08/664,872 (the “CIP Application”), which mice are (1) progeny of a cross of a Tg2576 N2 male with a C57B6SJL female or (2) the progeny of a cross between (Tg2576 N2 x C57B6SJL) male with a C57B6SJL female, (such mice referred to herein as” Stock”); (b) progeny of the Stock; and (c) certain transgenic mice that may result from the Sponsored Research Activities.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.